Methimazole NDC 33342-335

NDC codes

FDA NDC Directory

Product NDC (as listed)33342-335Labeler and product segments. Claims need a package NDC.

Product NDC at billing width33342-0335Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
33342-335-11	33342033511	100 TABLET in 1 BOTTLE (33342-335-11)Marketed from May 24, 2023
33342-335-12	33342033512	10 BLISTER PACK in 1 CARTON (33342-335-12) / 10 TABLET in 1 BLISTER PACKMarketed from May 24, 2023
33342-335-44	33342033544	1000 TABLET in 1 BOTTLE (33342-335-44)Marketed from May 24, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methimazole
Generic name (nonproprietary): methimazole
Active ingredients: Methimazole — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Macleods Pharmaceuticals Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209827
Marketing start: May 24, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Thyroid Hormone Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 33342-335_ea518c56-49d7-4770-8ded-21e443e71c3cSPL ID ea518c56-49d7-4770-8ded-21e443e71c3cSPL set ID 6f08df05-cc29-45ef-8f6e-12272bfbb0d7RxCUI 197941, 197942UNII 554Z48XN5EUPC 0333342335111, 0333342335449, 0333342336446, 0333342336118
Pharmacologic class: Thyroid Hormone Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N433342033511 followed by a unit qualifier and the quantity

Package 33342-0335-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 25, 2025.

Indications (excerpt from the label)

INDICATIONS & USAGE Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209827

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209827
Product	Strength	Form · route	Labeler	Product NDC
Methimazole	Methimazole 10 mg/1	TabletOral	Macleods Pharmaceuticals Limited	33342-336